Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Micrologix biotech -- Ignore unavailable to you. Want to Upgrade?

To: Larry G. who wrote (539)	8/21/1999 4:33:00 AM
From: Graham Dellaire	Read Replies (2) \| Respond to of 792

CDC Reports on Drug-Resistant Staph 01:10 AM ET 08/20/99 CDC Reports on Drug-Resistant Staph ATLANTA (AP) _ Federal health officials have confirmed the deaths of four Midwestern children linked to drug-resistant staph infections they acquired outside a hospital setting. Drug-resistant staph was once largely confined to hospitals and nursing homes, but the children's deaths in Minnesota and North Dakota show it may be spreading to communities, the Centers for Disease Control and Prevention said Thursday. ''These are the first deaths we're aware of that have appeared in the United States and in medical literature,'' said Dr. J. Todd Weber of the CDC's National Center for Infectious Diseases. ''How rare or how common it is, we don't know yet.'' The children, ages 1 to 13, acquired methicillin-resistant staphylococcus aureus infections between 1997 and 1999. None of the children had been recently hospitalized before their deaths, the CDC said. Staph bacteria are the No. 1 cause of hospital-acquired infections in the United States, blamed for 13 percent of the 2 million hospital infections annually. Half of staph bacteria infections contracted by hospital patients in 1997 were resistant to a large class of antibiotics, up from 1974, when only 2 percent were drug-resistant, the CDC said. Doctors recently have seen an increase in drug-resistant infections acquired outside of hospitals although CDC researchers said they don't know yet to what extent. ''The resistant bacteria have been around 30 years but these four cases suggest it may be getting into the general population,'' said Dr. Timothy Naimi, a medical epidemiologists with the CDC.

To: Larry G. who wrote (539)	8/21/1999 11:48:00 AM
From: Carter Berezay	Read Replies (1) \| Respond to of 792

Larry, Pete's comments are very valid. To a bystander a high salary and bonus always look bad on the surface. I know nothing about biotech salary levels but I do think management leaders should be compensated well for their efforts. The proof is in the pudding. Dany did orchestrate that last financing! Now it is up to Dany to lead MBI forward. He has put together a financing that will give MBI some breathing room for the forseeable future. It may look that they gave up a lot of shares for now but having been in similar situations I've learned it is best to take the money when it's available. Dany did just that. From what I hear MBI is going to have 4 drugs in Phase trials over the next 6 months - 226, acne, eye and an unspecified indication. When you think of it perhaps $15 million may not be too excessive. MBi will need a partner for all or some of their drugs soon enough. If 226 is as good as the trials indicate, MBI will get more for it in a partnership agreement (royalty-wise)once the next Phases are more advanced. Time to keep the momentum going! I expect a Phase II announcement from MBI within a very short time. The other drug candidates? Time will tell. It's show-time!!!!!! Carter B.